---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-036820"
form_type: "8-K"
ticker: "VKTX"
cik: "0001607678"
company_name: "Viking Therapeutics, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:44:14.266871+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Viking signs $150M manufacturing deal with CordenPharma for VK2735 supply

## Summary
- Viking prepays $150M over 2025-2028 for dedicated API and fill/finish capacity for obesity drug VK2735.
- CordenPharma commits to multi-ton annual API supply; dedicated lines for 100M autoinjectors and 100M vial/syringe units.
- Annual oral tablet capacity exceeds 1 billion units; capacities are expandable at Viking's option.
- Phase 3 subcutaneous VK2735 trial planned to start Q2 2025; oral Phase 2 VENTURE trial ongoing.

## SEC filing metadata
- accession: 0000950170-25-036820
- form_type: 8-K
- ticker: VKTX
- cik: 0001607678
- company_name: Viking Therapeutics, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607678/000095017025036820/0000950170-25-036820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607678/000095017025036820/vktx-20250310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-036820
- JSON: https://secwatch.observer/filing/0000950170-25-036820.json
- Plain text: https://secwatch.observer/filing/0000950170-25-036820.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.